Saudi Reaffirms Commitment to Bridging Global Divides, Driving Energy Transition, Inclusive Economic Growth at WEF23
25.1.2023 23:53:00 EET | Business Wire | Press release
Saudi Arabia reiterated its commitment to build bridges across geopolitical and economic divides at the World Economic Forum (WEF) 2023 Annual Meeting in Davos, Switzerland, last week.
His Highness Prince Faisal bin Farhan Al Saud, Minister of Foreign Affairs, led the Saudi delegation of nine ministers and high-level officials, and told the world that geopolitical stability is key to energy security, and the Kingdom has “become the meeting place between East and West.”
During the week, Saudi Arabia hosted a dialogue titled ‘Toward a Resilient Urban Resource Nexus,’ with key international public and private sector stakeholders from regional and global organizations discussing the sustainability of future cities.
His Highness Prince Faisal, Her Royal Highness Princess Reema, His Excellency Alswaha, His Excellency Alkhorayef and His Excellency Alibrahim participated in a multilateral meeting with WEF leadership, Klaus Schwab, Founder and Executive Chairman, and Børge Brende, President, to explore areas of mutual interest.
During the meeting, His Excellency Alswaha, Chairman of the Board of King Abdulaziz City for Science and Technology (KACST) and Chairman of the Board of The Research, Development and Innovation Authority (RDIA) and Brende, signed a Letter of Intent (LoI) to establish a new accelerator program to help ignite innovation in Saudi Arabia.
The Saudi delegates highlighted the Kingdom's role as a Pioneering Partner in the Forum's Global Collaboration Village, which will leverage the Metaverse to serve the global community.
Separately, the Ministry of Investment, in coordination with the Ministry of Energy and the Ministry of Industry and Mineral Resources, organized a high-level dialogue for executives from the energy, petrochemicals and mining sectors to discuss the impact of the energy transition, the role of petrochemical industries and investments needed to achieve net zero by 2060.
Meanwhile, Saudi Arabia’s Ministry of Economy and Planning – in collaboration with the WEF open innovation platform UpLink – launched a challenge to crowdsource transformative solutions to secure local food in countries impacted by low rainfall, drought and desertification.
The Food Ecosystems and Arid Climates Challenge is a global call for food entrepreneurs, start-ups, social ventures, and SMEs to submit solutions that incorporate low or high technologies or ancestral responses.
Also during the week, Saudi Arabia – represented by the Ministry of Economy and Planning – joined the WEF Jobs Consortium, a coalition of CEOs, IOs, ministers and other leaders with a common aim to promote a better future of work for all by enabling job creation and job transitions.
The Saudi Arabian delegation also engaged in a wide range of bilateral meetings, dialogues with global leaders, ministers and CEOs and – for the first time – public panel sessions as part of WEF’s Open Forum. These included discussions with high-level public and private sector representatives from several countries and were an opportunity to share the Kingdom’s vision while exploring potential partnerships and areas of collaboration.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005752/en/
Contact information
Wauod Alquaied
walquaied@mep.gov.sa
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom